|
注册号: Registration number: |
ChiCTR2300074821 |
|
最近更新日期: Date of Last Refreshed on: |
2024-01-09 22:15:31 |
|
注册时间: Date of Registration: |
2023-08-17 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
准分子激光微单眼视多焦双非球面消融模式矫正近视伴老视临床研究 |
|
Public title: |
Clinical study of excimer laser micro-monocular multi-focal double aspherical ablation mode for myopia and presbyopia correction |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
准分子激光微单眼视多焦双非球面消融模式矫正近视伴老视临床研究 |
|
Scientific title: |
Clinical study of excimer laser micro-monocular multi-focal double aspherical ablation mode for myopia and presbyopia correction |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
季鹏 |
研究负责人: |
季鹏 |
|
Applicant: |
Ji Peng |
Study leader: |
Ji Peng |
|
申请注册联系人电话: Applicant telephone: |
+86 135 7375 3812 |
研究负责人电话:
Study leader's |
+86 135 7375 3812 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
ji6605@126.com |
研究负责人电子邮件: Study leader's E-mail: |
ji6605@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
https://www.semeye.com/ |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
https://www.semeye.com/ |
|
申请注册联系人通讯地址: |
山东省济南市英雄山路48号 |
研究负责人通讯地址: |
山东省济南市英雄山路48号 |
|
Applicant address: |
48 Yingxiongshan Road, Jinan, Shandong |
Study leader's address: |
48 Yingxiongshan Road, Jinan, Shandong |
|
申请注册联系人邮政编码: Applicant postcode: |
250002 |
研究负责人邮政编码: Study leader's postcode: |
|
|
申请人所在单位: |
山东中医药大学附属眼科医院 |
||
|
Applicant's institution: |
Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
山东中医药大学附属眼科医院 |
||
|
Affiliation of the Leader: |
Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
HEC-KS-2020003KY |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山东中医药大学附属眼科医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Eye Hospital of Shandong University of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-05-18 00:00:00 | ||
|
伦理委员会联系人: |
李晓鹏 |
||
|
Contact Name of the ethic committee: |
Xiaopeng Li |
||
|
伦理委员会联系地址: |
山东省济南市英雄山路48号 |
||
|
Contact Address of the ethic committee: |
48 Yingxiongshan Road, Jinan, Shandong |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 531 5885 9695 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
山东中医药大学附属眼科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省济南市英雄山路48号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
48 Yingxiongshan Road, Jinan, Shandong |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
山东中医药大学附属眼科医院科研基金支持 |
||||||||||||||||||||||
|
Source(s) of funding: |
Scientific research fund of Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究疾病: |
老视 |
||||||||||||||||||||||
|
Target disease: |
presbyopia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
评价基于准分子激光微单眼视多焦双非球面消融模式矫正老视的安全性、有效性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the safety and effectiveness of excimer laser micro-monocular multi-focal double aspherical ablation mode in the correction of presbyopia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
所有患者均由同一医师完成手术。 术前常规消毒,表面麻醉,采用VisuMax飞秒激光系统(Carl Zeiss VisuMax,德国)制作角膜瓣,厚度100μm,直径8.1mm,边切角60°。制瓣完成后,采用SCHWIND AMARIS 1050RS准分子激光机(SCHWIND AMARIS,德国)行角膜基质层消融,主导眼选择Aberration-Free消像差切削,完全矫正屈光不正;非主导眼选择 PresbyMAX monocular消融模式,治疗完成后,平衡盐溶液瓣下冲洗,复位角膜瓣,用无屑吸血海绵抚平角膜瓣。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
All patients were operated on by the same physician. Routine disinfection and topical anesthesia were performed before operation. The corneal flap was made by VisuMax femtosecond laser system (Carl Zeiss VisuMax, Germany), with a thickness of 100μm, a diameter of 8.1mm and a cutting angle of 60. After the flap was made, the corneal stroma was ablated by SCHWIND AMARIS 1050RS excimer laser (Schwinder Amaris, Germany), and Aberration-Free anamorphic ablation was selected as the dominant eye to completely correct ametropia. PresbyMAX monocular ablation mode was used in non-dominant eyes. After the treatment, balanced salt solution washed under the flap, reset the corneal flap, and smoothed the corneal flap with a dust-free blood-sucking sponge. |
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.目前眼部有活动性炎症或感染; 2.术前角膜地形图及生物力学检查异常者。预期切削后角膜基质厚度<300um,术前中央角膜厚度<470um; 3.Pupil offset≥ 0.7mm; 4.不能耐受1D的屈光参差; 5.有除屈光不正外其他影响视力的眼病,眼科手术史(包括激光角膜屈光手术),外伤史等; 6.焦虑、抑郁等精神状态及对术后视觉质量与视力要求过高者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Current active inflammation or infection of the eye; 2. Those with abnormal preoperative corneal topography and biomechanical examination. Expected post-cutting corneal stromal thickness < 300um and preoperative central corneal thickness < 470um; 3. Pupil offset >= 0.7mm; 4. Intolerance to micro-monovision testing with contact lenses or trial frame for at least 1 D; 5. Have an eye condition that affects vision other than refractive error, history of ocular surgery (including laser refractive surgery) and traumatism; 6. Anxiety, depression and those who have high demands for postoperative visual quality and vision. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-03-01 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-03-01 00:00:00 至 To 2023-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成后6个月公开原始数据,临床试验公共管理平台http://www.medresman.org.cn/login.aspx |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Open the original data six months after the completion of the test, Resman: http://www.medresman.org.cn/login.aspx |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集病例记录表(Case Record Form, CRF)和手术前后相关检查均整合在电子病历记录中,二电子采集和管理系统(Electronic Data Capture, EDC)有医院信息可保管;所有原始数据可通过下面链接查看(https://pan.baidu.com/s/16_EZ_AN8eMXCPcZCDAbRVA)。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The case record form (CRF) and relevant examinations before and after the operation are integrated into the electronic medical record, and the electronic data capture (EDC) has hospital information to keep; All raw data can be viewed through the following link (https://pan.baidu.com/s/16_EZ_AN8eMXCPcZCDAbRVA). |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |